Related Experiment Video
Updated: Sep 28, 2026
Experimental Infection with Listeria monocytogenes as a Model for Studying Host Interferon-γ Responses
Published on: November 16, 2016
[Study on the biological activity and molecular mechanism of IFNalpha on human myeloma cell line Sko-007]
Lun Song1, Yan Li, Yingxun Sun
1Institute of Basic Medical Science, Academy of Military Medical Science, Beijing 100850, China.
Objective:
To investigate the biological activity and molecular mechanism of interferon alpha (IFNalpha) on human myeloma cell line Sko-007.
Methods:
The effect of IFNalpha on the growth of Sko-007 cells was measured by MTT assay. Cells cycle distribution and the expression of two IL-6 receptor chains (IL-6R and gp130) on Sko-007 cell surface in the absence or presence of IFNalpha were monitored by FACS analysis. The activation state of protein kinase ERK, which is involved in Ras/MAPK signal transduction pathway mediating cell survival and proliferation, and the expression of anti-apoptotic Bcl-2 family proteins-Bcl-2, Bcl-x(L) and Mcl-1 in Sko-007 cells with or without IFNalpha were determined by immunoblot assay.
Result:
IFNalpha arrested Sko-007 cell cycle progression. After stimulation with IFNalpha, an obvious increase in G(0)/G(1) phase (41.1%-->84.1%) and decrease in S phase (57.1%-->13.3%) of Sko-007 cell cycle distribution can be observed. Moreover, the proliferation of Sko-007 cells was dramatically inhibited in the presence of IFNalpha, with a maximal inhibitory rate up to 88%. In addition, the expression of gp130 on cell surface, the activation of protein kinase ERK and the expression of Bcl-2 and Bcl-x(L) were all down-regualted in IFNalpha-stimulated Sko-007 cells.
Conclusion:
The inhibitory effect of IFNalpha on the proliferation of Sko-007 cells was mediated by gp130 down-regulation, degradation of Bcl-2 family anti-apoptotic proteins and inhibition of ERK activation.
Insights
Interferon alpha (IFNalpha) inhibits human myeloma cell proliferation by down-regulating gp130, reducing anti-apoptotic proteins, and inhibiting ERK activation. This study reveals IFNalpha
Area of Science:
- Immunology
- Molecular Biology
- Cancer Research
Background:
- Interferon alpha (IFNalpha) is a cytokine with known immunomodulatory and anti-proliferative effects.
- Human myeloma cell lines provide a model for investigating therapeutic strategies against multiple myeloma.
Purpose of the Study:
- To elucidate the biological activity and molecular mechanisms of interferon alpha (IFNalpha) in the human myeloma cell line Sko-007.
- To determine how IFNalpha impacts cell cycle progression, proliferation, and key signaling pathways in myeloma cells.
Main Methods:
- MTT assay to assess cell proliferation.
- Flow cytometry (FACS) to analyze cell cycle distribution and cell surface receptor expression (IL-6R, gp130).
- Immunoblotting to evaluate protein kinase ERK activation and Bcl-2 family protein expression (Bcl-2, Bcl-x(L), Mcl-1).
Main Results:
- IFNalpha significantly inhibited Sko-007 cell proliferation by up to 88% and induced cell cycle arrest in the G0/G1 phase.
- IFNalpha treatment led to decreased expression of gp130, reduced activation of ERK protein kinase, and down-regulation of anti-apoptotic proteins Bcl-2 and Bcl-x(L).
Conclusions:
- The anti-proliferative effects of IFNalpha on Sko-007 myeloma cells are mediated through the down-regulation of gp130.
- Degradation of Bcl-2 family anti-apoptotic proteins and inhibition of ERK activation contribute to IFNalpha's mechanism of action.
- IFNalpha demonstrates potential as a therapeutic agent by disrupting key survival pathways in myeloma cells.
More Related Videos
08:26Development and Validation of an Ultrasensitive Single Molecule Array Digital Enzyme-linked Immunosorbent Assay for Human Interferon-α
Published on: June 14, 2018
07:20Ex vivo Expansion of Tumor-reactive T Cells by Means of Bryostatin 1/Ionomycin and the Common Gamma Chain Cytokines Formulation
Published on: January 14, 2011
